Teplizumab: The First Drug to Address Type 1 Diabetes at Its Root

For over 100 years, type 1 diabetes treatment has focused on replacing the insulin the body can no longer make. In November 2022, teplizumab (brand name Tzield) introduced a fundamentally different strategy: targeting the autoimmune process itself. Teplizumab is the first disease-modifying therapy approved by the FDA for type 1 diabetes, meaning it addresses the root cause—the immune system's mistaken attack on insulin-producing beta cells—rather than only managing its symptoms.

Teplizumab is a monoclonal antibody that works by targeting CD3 on T cells, the immune cells responsible for destroying beta cells. By slowing this autoimmune process, the drug can delay the progression of the disease, potentially giving the pancreas more time to preserve its remaining function.

Clinical trials have demonstrated that teplizumab can delay progression to stage 3 type 1 diabetes—the stage when insulin therapy becomes necessary—by up to three years in patients with preclinical (stage 2) disease. This delay can be significant for families preparing for diagnosis and for the overall health trajectory of a young person with type 1 diabetes.

In patients newly diagnosed with type 1 diabetes, teplizumab preserves beta-cell function. A large clinical trial showed that patients treated with teplizumab had significantly higher stimulated C-peptide levels at week 78 compared to those receiving placebo. C-peptide is a marker of the body's natural insulin production. Nearly 95% of patients treated with teplizumab maintained clinically meaningful C-peptide levels, compared to 79% of those receiving placebo.

An integrated analysis of data from over 600 patients across five trials confirmed this benefit persisted over time. At one year, teplizumab-treated patients showed an average increase in C-peptide, and at two years, this preservation was even more pronounced. Additionally, patients treated with teplizumab required lower doses of injected insulin to manage their blood sugar effectively.

Teplizumab has been studied in approximately 1,018 patients across multiple clinical trials, accumulating roughly 1,500 patient-years of follow-up data among those treated with the drug. Safety data show a consistent profile across these studies.

The most common adverse events include lymphopenia (low white blood cell counts), rash, and headache. Importantly, the majority of these side effects occurred during and shortly after the first few weeks of teplizumab administration and generally resolved without additional treatment. Adverse events occurred primarily during the infusion process itself.

Teplizumab's development represents decades of work by researchers and organizations dedicated to type 1 diabetes. In the late 1980s, endocrinologist Kevan Herold, M.D., and immunologist Jeff Bluestone, Ph.D., collaborated at the University of Chicago. Dr. Herold's own diagnosis with type 1 diabetes motivated his research focus. Early studies showed that an anti-CD3 antibody—which became teplizumab—could delay the onset of type 1 diabetes. These findings, supported by organizations like Breakthrough T1D, led to the first clinical trials of a disease-modifying therapy for the condition and ultimately to FDA approval.

It's important to be clear about what teplizumab does: it delays progression and preserves insulin production, but it is not a cure. People treated with teplizumab will still develop type 1 diabetes, though the timing and severity may be different. For those already diagnosed, it helps protect remaining beta-cell function but does not eliminate the need for insulin therapy.

Teplizumab is currently approved for patients 8 years of age or older with stage 2 type 1 diabetes and has also shown benefits in newly diagnosed stage 3 patients. As research continues, scientists are exploring additional strategies, including nutrition interventions and early insulin therapy guided by continuous glucose monitors, to further improve outcomes for people with type 1 diabetes at all stages.

Origin: breakthrought1d.org (News report). Evidence: News report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.